Ultrasensitive blood test predicts head and neck cancer relapse months earlier

A new study by investigators from Mass General Brigham Cancer Institute has found that an ultrasensitive blood test called HPV-DeepSeek could help identify which people with HPV-associated head and neck cancer still had cancer cells in their bodies after surgery and may benefit the most from additional treatments. The results are published in Science Translational Medicine.